The mortality in patients with intermittent claudication can be reduced by treatment with ticlopidine. This is the clinically most significant result from STIMS, the Swedish Tlclopidine Multicenter Study. During an average treatment period of 5.6 years, 153 of the 687 patients died, 26.1% in the placebo group and 18.5% in the ticlopidine group (RRO.7, p=0.015). The incidence of fatal vascular events in the two groups was 12% and 6%. In terms of lives saved per years of treatment, STIMS showed that by treating 200 claudicants for 5 years one can save 13 from a cardiovascular death, not merely dying from something else as treatment was associated with a reduced total mortality as well. The interpretation of the on-treatment analysis is that for those who tolerate the drug the combined vascular morbidity and mortality rate is lowered from 24% to 14%. The disadvantage is that many patients do not tolerate ticlopidine. In STIMS, 22% (2.5 times as many as in the control group) had to stop medication because of gastrointestinal side-effects. Although ticlopidine is associated with an increased risk of leukopenia, the risk in absolute numbers is small: according to STIMS, 4% during 5.6 years. All events were reversible. The 1.4% incidence of thrombocytopenia did not seem to be associated with ticlopidine treatment.
The clinical problem
In most cases it is the walking-induced calf pain that makes patients with peripheral arterial disease see a doctor. If the doctor is a vascular surgeon, the treatment offered may be reconstructive vascular surgery or angioplasty, which in many cases is an appropriate measure given that the patient's true problem is stenosis verified angiographically in one of the common iliac arteries. In most cases it is not. If our vascular surgeon's treatment outcomes are similar to those that have been reported from the Swedish Vascular Registry (Swedevasc), it means that about 10% of the patients will not attend the scheduled follow-up I year later because they will be dead. I More than half of them from vascular disease, not in the legs but from an occluding thrombus in one of the coronary vessels or from a rupture of thrombus or an embolus in the brain vessels. So although vascular surgery or angioplasty in many cases may lead to a complete restoration of leg blood flow it does not solve these patients' major problem, i.e. the high and fairly imminent threat of a fatal myocardial infarction and stroke.
Treatment options
If treatment actually means prevention or postponement of a vascular death, what then is the best, i.e. the most costeffective, option? Well, if the answer has to be founded on scientific evidence, the truth is we do not know. For, although there is at least circumstantial evidence of how Department of Community Medicine, Lund University, Sweden progression of atherosclerotic disease can be stopped or delayed by smoking cessation and somewhat better evidence of the corresponding preventive effects of lipid and blood pressure lowering treatments, the actual fact is that the efficacy of these treatments in the prevention of vascular death in patients with intermittent claudication has not been evaluated in control trials. But even if we were convinced about the efficacy of this type of risk factor intervention, it cannot be assessed as a treatment option until we know something about its costs and effectiveness. If only 10% of the claudicants quit smoking for good and if, as in Sweden, 40% of the ones who are treated for hypertension and an even greater proportion of the ones treated for hyperlipidemia do not get their blood pressure or lipids under control, it does not seem reasonable to assume that a treatment program focusing on these three cardiovascular risk factors would be a very cost-effective strategy. It depends, of course, on the long-term treatment goal: the number of deaths we aim to prevent.
So what treatment can we and should we offer the next c1audicant? Platelet antiaggregatory treatment? My answer is yes, but the ultimate decision must be left with the patient who, if he is well educated, expects and maybe even requires from his knowledgeable doctor answers to these three questions: 'What are my chances if I abstain from the treatment that you recommend, doctor?' 'How much do I improve my prognosis by taking the medication?' 'What are the known side-effects and what is the probability that I will get an adverse event?' If these are the questions and you are thinking of ticlopidine it may then be appropriate to turn to STIMS, the Swedish Ticlopidine Multicenter Study, for an answer."
Patients included in STIMS
The c1audicants in STIMS had at randomization, or previously, as many of them had been successfully treated by vascular surgery, a history of walking-induced calf pain that disappeared within 10 min after resting and an arm-ankle pressure gradient exceeding at least 10 mmHg. The 687 patients in STIMS are not a random sample from the population of c1audicants and cannot be considered a representative sample from that population because patients older than 70 years, patients with rest pain and gangrene, pregnant women and women of fertile age, patients with bleeding disorders, cancer, kidney and liver diseases, patients with a myocardial infarction or stroke within the previous 3 months and patients with diabetes requiring insulin were not eligible for the trial. With these inclusion and exclusion criteria we ended up with 525 men and 162 women whose average was 60 years. One out of three had been hospitalized for reconstructive vascular surgery. More than half of them had a duration of symptoms exceeding 3 years, 95% of them were, or had been, smokers, about one-third had a systolic blood pressure above 160 mmHg, 55% a cholesterol value exceeding 6.2 mmol and 7% had type 2 diabetes. About 40% had angina or a previous myocardial infarction. If this account reminds you of your own patients, then you can at least have some faith in the reliability of your answers to the three questions above by using data from STIMS.
What happened to the patients that did not receive ticlopidine?
All patients were given advice and help to quit smoking and all those with hypertension, hyperlipidemia and diabetes were given appropriate treatment. The achieved change in exposure to these three risk factors was not encouraging. The average systolic and diastolic blood pressure and the average serum cholesterol remained practically unchanged, although these patients were seen every third month by doctors and nurses with a professional background in the treatment of atherosclerotic disease. The percentage of smokers decreased from 67% to around 60% during the study period.
When the trial was stopped, after an average 5.6 years of treatment, 89 patients (26.1%) had died in the placebo group, 26 of them of an acute myocardial infarction, three of stroke. Another 14 had died suddenly or were found dead at home. The death certificate in each of these cases listed chronic ischemic heart disease as the underlying cause of death. The incidence of cardiovascular endpoints in the placebo-treated group was 24%. Forty-nine percent of the first cardiovascular events in patients treated with placebo were fatal. So the answer to the patient inquiring about his odds without antiplatelet therapy is not encouraging, one out of five will, in less than 6 years from now, get a myocardial infarction, one out of ten a stroke, but more serious is that 20% will no longer be alive.
Does ticlopidine treatment change the prognosis?
What is the prognosis then, if patients comply with the recommended therapy, 250 mg toclipidine twice a day? This Vascular Medicine 1996; 1: [141] [142] [143] is what 346 patients were randomly allocated in STIMS. The clinical features of these patients were very similar to the ones in the placebo-treated group. The incidence of cardiovascular endpoints in the ticlopidine group was 19%. This endpoint was a fatal event in one case out of three. At the time the treatment code was broken, 64 (18.5%) of the ticlopidine-treated patients had died (89 in the placebo group), 15 of an acute myocardial infarction and one of a stroke. According to necropsy reports, another seven patients died of chronic ischemic heart disease. The 29% lower mortality rate in the ticlopidine-treated group after 5.6 years of treatment was entirely explained by this lower mortality from vascular diseases. Other causes of death were similar in the two groups.
So the good news for the c1audicant who considers ticlopidine treatment is that the risk of 'a fatal vascular event during the 5-6 years to come goes down from an average 12% to 6%. From the public-health-oriented doctors' perspective it means, in terms of lives saved per years of treatment, that, if 200 c1audicants are treated for 5 years on average, 13 are saved from a cardiovascular death -but not merely to die from something else, as ticlopidine treatment turned out to be associated with a reduced total mortality as well.
What are the side-effects?
The bad news for the patient is that there is a 20% chance that he or she will not tolerate the drug. This may sound serious but it should be pointed out that in this double-blind trial one out of 12 placebo-treated patients was withdrawn from treatment because of claimed adverse events. Diarrhoea, which was one of the potential side-effects listed on the written informed consent, was reported by 30 patients in the control group and by 75 in the ticlopidine group.
Forty-five percent of the patients in the ticlopidine group were reported to have an adverse event; 16 (about 5%) had a hemorrhagic event (epistaxis, melena and hemoptysis and other unspecified hemorrhagic episodes). Five of these cases were considered serious enough to withdraw treatment.
Another 5% of the patients had cutaneous side-effects, most of them a rash or pruritus. Treatment was stopped permanently for nine of them. The six cases (2%) with hepatic side-effects were all cases with abnormal, albeit moderately increased, liver enzymes (alkaline phosphatase, aspartate aminotransferase, alanine aminotransferase, gammaglutamyltransferase).
Seven of the ticlopidine-treated patients had a hematological adverse event. Two of these were cases with leucopenia, three had thrombocytepenia, one patient had both leuko-and thrombocytopenia, and one pancytopenia. This latter case later turned out to be an early case of Hodgkin's lymphoma. The other six cases were considered mild to moderate and were all reversible on discontinuation of treatment. Another eight of the ticlopidine-treated patients had, on at least one occasion, an unreported white cell count below 3.5 x lOY/liter. These events had no clinical correlation, they did not lead to withdrawal of medication and all remained stable or reverted spontaneously to normal.
What is the probability of an adverse reaction?
As indicated previously, placebo treatm~nt was not without side-effects. This fact needs to be considered for a proper assessment of the risks associated with a recommended treatment. The incidence of adverse events in patients treated with placebo was not 0% but .26%! The 4% incidence of cutaneous side-effects was only somewhat lower than it was in the ticlopidine group and rash and pruritus were, as in the ticlopidine group, the most common manifestations.
Hepatic side-effects occurred with the same frequency as in the ticlopidine group.
. , The nine cases (2.5%) with hemorrhagic events In the placebo group were all considered mild and did in no case lead to permanent withdrawal of treatment.
In the placebo-treated group, there. were .no reported hematological adverse events. Three patients did, however, on at least one occasion have a white cell count below 3.5 x 10 9/1iter and another five patients had, similarly, on at least one occasion, an unreported platelet count below lOOOOO/liter. None of these cases was associated with clinical symptoms.
So what can be concluded is that ticlopidine treatment in comparison with placebo is associated with a four times higher risk of reversible leukopenia during a 5.6-year treatment period. In absolute numbers, however, this means that the average ticlopidine-treated claudicant's chance of not getting leukopenia is 96% while the corresponding placebotreated patient's chance of avoiding it is 99%. The 1.4% incidence of thrombocytopenia in STIMS did not seem to be associated with ticlopidine treatment. Other potential complications that should be considered are hemorrha~ic events; the 5% incidence in the ticlopidine group was twrce as high as that observed in the placebo group. The most common and in one respect the most serious adverse event associated with ticlopidine, because it prevented further treatment for so many, was diarrhea and other gastrointesti-Vascular Medicine 1996; 1: 141-143
The STIMS trial 143 nal symptoms; an incidence of 22% in the ticlopidine group means that it was 2.5 times more frequent in that group than it was in the placebo group.
Efficacy versus effectiveness
The intention to treat analysis that has been referred to so far is of course pertinent and appropriate from a safety and an effectiveness perspective. Such an analysis is, however. of limited value for the doctor and his next patient as it does not generate a reliable estimate of the risk reduction that can be achieved in patients who are lucky enough to tolerate the drug. The combined vascular morbidity and mortality for those who did was lowered from 24% to 14% in STIMS, a risk reduction of 41%.
In Sweden, peripheral vascular disease is not an approved indication for treatment with ticlopidine. The view taken by the medical authorities is that due to the high incidence of side-effects with ticlopidine it cannot be considered a cost-effective treatment strategy to reduce the vascular morbidity and mortality in the claudicant population. To me as a doctor, it seems strange to use that as an argument for not offering patients. who are lucky enough to tolerate it, a drug that may reduce the probability of a fatal first vascular event during the coming 5-6 years from I in 10 to I in 20, slow down the progression of leg atherosclerosis and reduce the need of vascular surgery.
